Download PDF
Market: Hong Kong Ticker: 690 ISIN: KYG9198H1406 Industry: Healthcare
Uni-Bio Science Group Ltd is a leading Chinese biopharmaceutical healthcare company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market.  The Company is focused on addressing high unmet medical needs via the development and commercialisation of highly innovative therapies.

Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).

Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.

Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.

Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – diabetes, ophthalmology and dermatology. 

 Marketed products

 Lead clinical development programs

  • GeneTime® - Dermatology
  • GeneSoft® - Ophthalmology
  • Pinapu® - Fungal infections
  • Mitiglinide – Type-2 diabetes
  • Uni-E4 – Type-2 diabetes
  • Uni-PTH - Osteoporosis and ostealgia

Expansion Strategy
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function. 
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
Uni-Bio’s ultimate goal is to build a leading, sustainable organization that builds and delivers shareholder value by efficiently executing a number of growth strategies.

Share Data 21/07/2017
Currency HKD Volume 10,445,000
Previous Close 0.174 Number of Shares 5,137,488,147
Change (%) 0.58 Market Cap (mil) 893.92
Key Figures (HK$’000) 9M 2014(1) 12M 2015 12M 2016
For the period/year ended 31 March/31 December(1)
Revenue 91,793 123,364 146,489
Gross profit 76,664 102,756 123,864
EBITDA (2,996) (24,653) (24,659)
(Loss)/Profit for the year/period (42,434) (59,799) (55,727)
As at 31 March/31 December(1)
Total assets 596,668 556,956 497,321
Total liabilities (33,543) (50,296) (50,917)
Total equity 563,125 506,660 446,404
Total fixed assets 134,715 124,777 103,328
Earnings Per Share (HK cents)
Basic (0.87) (1.20)
(1.09)
Diluted (0.87) (1.20)
(1.09)
Financial Indicators
Gross profit margin (%) 83.5 83.3 84.6
Current ratio (times) 5.6 3.3 2.7
Total liabilities to total asset ratio (%) 5.6 9.0 10.2
Debt to equity ratio(2) (%) 6.0 9.9 11.4
Notes:
(1) During the financial period of 2014, the reporting period end date of the Company and its subsidiaries (collectively referred to as the “Group”) was changed from 31 March to 31 December.
(2) Ratio equals to total liabilities/total equity.

Share Data 21/07/2017
Currency HKD
Previous Close 0.174
Change (%) 0.58
Volume 10,445,000
Number of Shares 5,137,488,147
Market Cap (mil) 893.92

Key Figures (HK$’000) 9M 2014(1) 12M 2015 12M 2016
For the period/year ended 31 March/31 December(1)
Revenue 91,793 123,364 146,489
Gross profit 76,664 102,756 123,864
EBITDA (2,996) (24,653) (24,659)
(Loss)/Profit for the year/period (42,434) (59,799) (55,727)
As at 31 March/31 December(1)
Total assets 596,668 556,956 497,321
Total liabilities (33,543) (50,296) (50,917)
Total equity 563,125 506,660 446,404
Total fixed assets 134,715 124,777 103,328
Earnings Per Share (HK cents)
Basic (0.87) (1.20)
(1.09)
Diluted (0.87) (1.20)
(1.09)
Financial Indicators
Gross profit margin (%) 83.5 83.3 84.6
Current ratio (times) 5.6 3.3 2.7
Total liabilities to total asset ratio (%) 5.6 9.0 10.2
Debt to equity ratio(2) (%) 6.0 9.9 11.4
Notes:
(1) During the financial period of 2014, the reporting period end date of the Company and its subsidiaries (collectively referred to as the “Group”) was changed from 31 March to 31 December.
(2) Ratio equals to total liabilities/total equity.